> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pfizer pays $330 million upfront for Starna's in vivo CAR-Ts, with U.S. clinical manufacturing built in
- URL: https://chinapharmadesk.com/pfizer-starna-in-vivo-cart-deal/
- Published: 2026-11-19T02:48:56.000Z
- Updated: 2026-11-19T03:29:01.000Z
- Description: Pfizer Inc. (NYSE: PFE) will pay Suzhou's Starna Therapeutics $330 million upfront and up to $2.3 billion in milestones for ex-China rights to three pre-IND in vivo CAR-Ts (STR-P004, NCT07003178), with U.S. CMC.
- Author: Lin Yi
- Tags: Desk analysis, Deals & BD, Autoimmune & Immunology

[Pfizer Inc.](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-starna?ref=chinapharmadesk.com) (NYSE: PFE) announced on November 18, 2026 that it will pay Suzhou-based [Starna Therapeutics](https://en.starnatx.com/?ref=chinapharmadesk.com) $330 million upfront and up to $2.3 billion in development and commercial milestones for exclusive rights outside Greater China to three pre-IND *in vivo* chimeric antigen receptor T-cell (CAR-T) programs targeting autoimmune diseases. Although the three candidates (`STR-P004`, `STR-P005` and `STR-P006`) have not yet entered formal U.S. or Chinese registrational IND tracks, Starna has already dosed systemic lupus erythematosus (SLE) and non-Hodgkin lymphoma (NHL) patients in Suzhou investigator-initiated trials (IITs, alongside registered lymphoma study [NCT07003178](https://clinicaltrials.gov/study/NCT07003178?ref=chinapharmadesk.com)), reporting complete peripheral B-cell depletion within 72 hours of a single intravenous infusion without lymphodepleting chemotherapy. Under the agreement, Pfizer will manufacture the finished drug product for initial clinical trials at its own U.S. facilities and holds an option to expand the license to include Greater China.

## Why a “pre-IND” Chinese package commanded $330 million upfront

On paper, $330 million in upfront cash for three preclinical candidates is an outlier for a licensing transaction that leaves Greater China rights behind. Even before Pfizer’s check, Starna—founded in August 2021 in Suzhou Industrial Park by chief executive Rongkuan (Frank) Hu, Ph.D., and scientific co-founder Qiang Cheng, Ph.D.—had raised roughly $106 million across three disclosed venture rounds: [RMB 150 million (approx. $22.1 million) in a May 2022 Series A](https://www.starnatx.com/news/21?ref=chinapharmadesk.com) led by LYFE Capital; [over RMB 300 million (approx. $44 million) in an October 2025 Series B](https://en.starnatx.com/news?ref=chinapharmadesk.com) co-led by LYFE Capital, Hillhouse Capital and Lilly Asia Ventures; and nearly $40 million in a May 2026 Series B+ round. Pfizer’s upfront payment alone is more than three times Starna’s cumulative venture capital.

The valuation gap is explained by what Chinese hospital IITs allow before a formal IND is cleared. In China, tertiary-hospital ethics committees can authorize first-in-human dosing of cell and gene therapy constructs under investigator-initiated protocols faster than a commercial IND package can clear the Center for Drug Evaluation (CDE) or the U.S. Food and Drug Administration (FDA); see our [China Pharma Glossary](https://chinapharmadesk.com/china-pharma-glossary/) for how IIT data feed cross-border licensing packages.

In October 2025, when Starna closed its Series B, chief business officer Elliott Sun disclosed in an [interview reported by Endpoints News](https://www.packgene.com/frontier/102225-starna-therapeutics/?ref=chinapharmadesk.com) that a single low-dose intravenous infusion of Starna’s lead *in vivo* CAR-T candidate (`STR-P004`) had reduced circulating B cells to zero cells per microliter on flow cytometry within 72 hours in an initial group of SLE patients and one relapsed/refractory NHL patient, accompanied by tissue B-cell depletion on biopsy, only mild cytokine release syndrome (CRS), and no lymphodepleting chemotherapy. Alongside those autoimmune IITs, Starna registered [NCT07003178](https://clinicaltrials.gov/study/NCT07003178?ref=chinapharmadesk.com), a 30-patient open-label dose-escalation study in Suzhou evaluating weekly intravenous doses of `STR-P004` (Days 1, 8, 15 and 22 of a 28-day cycle) in relapsed or refractory CD19-positive B-cell NHL.

For Pfizer, buying at the pre-IND transition captures human pharmacodynamic proof—B-cell clearance without chemotherapy conditioning—before Starna locks in a formal FDA IND protocol or CMC master file, allowing Pfizer to run global clinical development on its own regulatory and chemistry, manufacturing and controls (CMC) specifications.

## Spleen-targeted LNPs and an internal hepatic microRNA kill switch

The technical problem in non-viral *in vivo* CAR-T is keeping lipid nanoparticles (LNPs) out of the liver. Conventional LNPs bind apolipoprotein E in circulation and accumulate preferentially in hepatocytes. Starna’s `STAR-LNP` architecture—detailed across its platform disclosures and recent extrahepatic delivery papers by Hu and Cheng in [*ACS Nano* (2026)](https://en.starnatx.com/?ref=chinapharmadesk.com) and *Acta Pharmaceutica Sinica B* (January 2026)—combines three layers of control:

1. **Tissue-specific lipid chemistry (`tsLNP`)**: A combinatorial library of thousands of synthetic lipids screened to shift systemic biodistribution away from hepatic uptake and toward lymphoid organs, specifically the spleen.
2. **Cell-selective antibody conjugation (`csLNP`)**: Surface functionalization of the spleen-directed LNP with full-length antibodies that bind T-cell surface receptors, steering the mRNA payload into cytotoxic T cells.
3. **An embedded hepatic microRNA kill switch**: Because even spleen-enriched LNPs retain residual liver exposure, Starna builds a liver-specific microRNA target sequence into the CAR mRNA construct. If an LNP enters a hepatocyte, endogenous liver microRNAs bind the sequence and silence translation before CAR proteins can be expressed on liver cells.

Because mRNA-encoded CARs do not integrate into the T-cell genome, CAR expression is transient and controllable through repeat dosing—a profile suited to B-cell-driven autoimmune disorders where permanent B-cell aplasia and insertional mutagenesis carry a lower tolerance threshold than in late-line leukemia or myeloma. Alongside `STR-P004` (anti-CD19 linear mRNA), Starna has disclosed work on a dual-CAR construct targeting both `CD19` and `BCMA` and a circular RNA format (`STR-P005` / `STR-P006`) designed to extend intracellular translation duration.

Under the November 18 agreement, Pfizer receives more than the three autoimmune candidates. It also gains rights to deploy Starna’s *in vivo* CAR-T delivery platform across inflammation, immunology and oncology, options to exclusively license compounds generated under a separate research collaboration, and an option to acquire Greater China (`mainland China, Hong Kong, Macau and Taiwan`) development and commercialization rights for each licensed product.

## Onshore U.S. clinical manufacturing as a supply-chain and biosecurity firewall

One sentence in Pfizer’s release stands out for cross-border operations teams: Pfizer “plans to manufacture the finished drug product for the initial clinical trials using its facilities in the United States.”

Unlike autologous *ex vivo* CAR-T—which requires patient leukapheresis, cold-chain cell transport, viral vector transduction, and vein-to-vein turnaround across certified hospital centers—an LNP-mRNA *in vivo* CAR-T is an off-the-shelf sterile vial manufactured on the same unit operations Pfizer scaled globally for its COVID-19 mRNA vaccine `Comirnaty`. By transferring Starna’s lipid and RNA formulation directly into Pfizer’s U.S. plants for Phase 1 material:

- Pfizer avoids shipping biological samples or finished clinical vials across the Pacific and bypasses China’s Human Genetic Resources Administration (`HGRA`) export filings for ex-China trials;
- Global clinical supply is insulated from U.S. federal procurement and contracting restrictions ahead of the Office of Management and Budget’s (`OMB`) December 18, 2026 `BIOSECURE Act` list deadline, examined in our [WuXi AppTec 1260H and OMB biosecurity analysis](https://chinapharmadesk.com/wuxi-apptec-1260h-removal-omb-deadline/); and
- CMC release testing and IND comparability start inside FDA-inspected U.S. facilities from Day 1, rather than requiring a mid-clinical comparability bridge between a Chinese CDMO and a Western commercial plant—a friction point that China’s own regulators are trying to address domestically through [Order No. 828 segmented manufacturing rules](https://chinapharmadesk.com/china-nmpa-sponsor-transfer-segmented-manufacturing/).

## The 2025–2026 global *in vivo* CAR-T ledger: Western buyouts vs. China licenses

Pfizer is the sixth major multinational to buy into *in vivo* CAR-T over the past 20 months, following AstraZeneca, AbbVie, Gilead Sciences (via Kite Pharma), Bristol Myers Squibb and Eli Lilly. Placing all eight transactions side by side reveals a clear structural split between how big pharma acquires U.S. or European platforms and how it structures deals with Chinese originators:

| Date             | Buyer / Licensee                     | Originator (HQ)                                                             | Deal Structure                          | Upfront Cash           | Total Headline Value           | Vector & Payload                                    | Lead Asset & Stage at Signing                                                      |
| ---------------- | ------------------------------------ | --------------------------------------------------------------------------- | --------------------------------------- | ---------------------- | ------------------------------ | --------------------------------------------------- | ---------------------------------------------------------------------------------- |
| **Nov 18, 2026** | **Pfizer** (NYSE: PFE)               | **Starna Therapeutics** (Suzhou, China)                                     | Ex-Greater China license + China option | **$330 million**       | **$2.63 billion** \+ royalties | Spleen/T-cell targeted LNP + mRNA / circRNA (csLNP) | STR-P004, STR-P005, STR-P006 (Pre-IND autoimmune; human SLE/NHL IIT data in China) |
| **Apr 20, 2026** | **Eli Lilly** (NYSE: LLY)            | **Kelonia Therapeutics** (Boston, U.S.)                                     | 100% acquisition                        | **$3.25 billion**      | **Up to $7.0 billion**         | Engineered lentiviral particle (iGPS)               | KLN-1010 (BCMA; Phase 1 Australia in r/r MM, 4/4 MRD-negative)                     |
| **Feb 2026**     | **Eli Lilly** (NYSE: LLY)            | **Orna Therapeutics** (Watertown, U.S.)                                     | 100% acquisition                        | Undisclosed            | **Up to $2.4 billion**         | Immunotropic LNP + engineered circular RNA (oRNA)   | ORN-252 (CD19; clinical-trial-ready in autoimmune disease)                         |
| **Oct 16, 2025** | **Gilead / Kite** (NASDAQ: GILD)     | **Pregene Biopharma** (Shenzhen, China)                                     | Global R&D & license collaboration      | **$120 million**       | **Up to $1.64 billion**        | Lentiviral / *in vivo* CAR-T construct engineering  | Discovery / preclinical *in vivo* CAR-T programs in oncology & autoimmune disease  |
| **Oct 10, 2025** | **Bristol Myers Squibb** (NYSE: BMY) | **Orbital Therapeutics** (Cambridge, U.S.)                                  | 100% acquisition                        | **$1.5 billion**       | **$1.5 billion** cash          | Targeted LNP + circular RNA                         | OTX-201 (CD19; IND-enabling in B-cell autoimmune disease)                          |
| **Aug 21, 2025** | **Gilead / Kite** (NASDAQ: GILD)     | **Interius BioTherapeutics** (Philadelphia, U.S.)                           | 100% acquisition                        | **$350 million**       | **$350 million** cash          | Engineered lentiviral vector (T/NK cells)           | INT2104 (CD20; Phase 1 in B-cell malignancies)                                     |
| **Jun 30, 2025** | **AbbVie** (NYSE: ABBV)              | **Capstan Therapeutics** (San Diego, U.S.)                                  | 100% acquisition                        | **Up to $2.1 billion** | **Up to $2.1 billion** cash    | Antibody-targeted LNP (tLNP) + mRNA                 | CPTX2309 (CD19; Phase 1 in B-cell autoimmune disorders)                            |
| **Mar 17, 2025** | **AstraZeneca** (LSE: AZN)           | **EsoBiotec** (Mont-Saint-Guibert, Belgium; partnered with China’s Pregene) | 100% acquisition                        | **$425 million**       | **Up to $1.0 billion**         | Nanobody-lentiviral vector (ENaBL)                  | ESO-T01 (BCMA; China IIT in 4 r/r MM patients published in *The Lancet*)           |

Three patterns emerge from that ledger:

1. **Modality sorting by indication**: Every major *in vivo* CAR-T deal aimed primarily at **autoimmune disease** (`Capstan`, `Orbital`, `Orna` and now `Starna`) uses **targeted LNP + RNA (mRNA or circular RNA)** for transient, non-integrating B-cell reset without lymphodepletion. Conversely, deals anchored in **multiple myeloma or B-cell lymphoma** (`EsoBiotec`, `Interius`, `Kelonia`) rely on **retargeted lentiviral vectors** to achieve permanent genome integration and durable tumor clearance.
2. **M&A in the West vs. structured licensing in China**: Across the six U.S. and European targets, multinational buyers bought 100% of the equity for $350 million to $3.25 billion upfront. In China (`Pregene` with Kite at $120 million upfront; `Starna` with Pfizer at $330 million upfront), buyers avoided cross-border corporate takeovers in favor of licensing ex-China rights, internalizing clinical manufacturing in the U.S., and leaving early China clinical execution—or a future China buyout option—on a separate track.
3. **China’s dual role as clinical accelerator and price pressure-cooker**: Even AstraZeneca’s $1.0 billion acquisition of Belgium-based EsoBiotec was catalyzed by a four-patient investigator-initiated myeloma study run in China with Shenzhen’s Pregene Biopharma. At the same time, China’s domestic autologous CAR-T market has just been repriced to **RMB 288,600 (approx. $39,900)** per infusion under the 2026 National Reimbursement Drug List (`NRDL`) for [JW Therapeutics’ relma-cel](https://chinapharmadesk.com/china-nrdl-relma-cel-cart-payment/)—forcing Chinese cell-therapy developers (including JW Therapeutics itself, which unveiled an in-house lentiviral *in vivo* CAR-T platform on November 15) to pivot toward off-the-shelf *in vivo* platforms that can survive both Chinese reimbursement ceilings and global licensing competition.

The next records that would change this reading are peer-reviewed or conference publication of Starna’s full SLE and NHL IIT patient counts, B-cell recovery kinetics, and autoantibody seroconversion data from Suzhou (`NCT07003178`); Pfizer’s first U.S. IND filings and technology-transfer completion for U.S. clinical drug-product lots across the three licensed autoimmune programs; and whether Starna files parallel China Class 1 INDs with the CDE—or whether Pfizer exercises its option to fold Greater China rights into the global program.